precis
role
interleukin
il
breast
cancer
clear
previou
studi
suggest
tumorpromot
role
breast
cancer
wherea
recent
discoveri
activ
expand
tumorresid
cell
challeng
tradit
view
investig
role
breast
cancer
patient
grade
iii
stage
iia
iib
insitu
invas
ductal
carcinoma
compar
canon
cell
growth
factor
first
observ
breast
cancer
patient
present
higher
serum
level
healthi
control
upon
prolong
tcr
stimul
peripher
blood
cell
breast
cancer
patient
tend
undergo
apoptosi
could
prevent
addit
andor
cytotox
tcractiv
cell
also
enhanc
exogen
andor
interestingli
demonstr
synergist
effect
sinc
enhanc
cell
function
cytokin
ad
greater
sum
improv
mediat
individu
cytokin
could
promot
prolifer
cell
could
significantli
enhanc
promot
cell
prolifer
addit
cytotox
tumorinfiltr
cell
breast
tumor
elev
present
either
one
absent
synergist
effect
stop
regulatori
cell
treg
deplet
cell
numberdepend
manner
togeth
result
demonstr
could
work
synergist
improv
surviv
prolifer
cytotox
activ
cell
effect
suppress
treg
cell
interleukin
il
pleiotrop
cytokin
complic
role
tumor
progress
antitumor
immun
oft
could
suppress
express
mhc
class
ii
antigenpres
cell
hashimoto
et
al
promot
altern
activ
macrophag
nakamura
et
al
could
also
limit
extent
inflamm
inhibit
express
proinflammatori
cytokin
cell
macrophag
ouyang
et
al
function
might
suppress
antitumor
immun
essenti
suppress
tumorpromot
inflamm
oft
phosphoryl
cell
macrophag
critic
prevent
inflammatori
bowel
diseas
common
preced
event
colorect
cancer
mager
et
al
interestingli
sever
recent
studi
indic
also
promot
antitumor
immun
proinflammatori
action
mice
succumb
rapid
tumor
metastasi
lack
intratumor
expans
cell
reduc
major
histocompat
complex
mhc
molecul
mumm
et
al
inject
pegyl
significantli
elev
level
interferon
ifn
granzym
tumor
mumm
et
al
mumm
oft
addit
requir
activ
tumorresid
lymph
noderesid
cell
emmerich
et
al
togeth
partial
contrast
result
suggest
role
tumor
like
contextdepend
human
breast
cancer
common
malign
major
caus
cancerrel
death
women
torr
et
al
well
understood
immun
system
play
crucial
role
prognosi
breast
cancer
standish
et
al
http
elsevi
ltd
right
reserv
exact
mechan
underli
patholog
still
unknown
like
tumor
role
breast
cancer
also
unclear
breast
cancer
patient
tend
present
elev
serum
hamidullah
changkija
konwar
signific
correl
concentr
breast
cancer
prognosi
depend
patient
cohort
type
treatment
locat
studi
demonstr
higher
level
associ
wors
diseas
statu
chavey
et
al
hamidullah
changkija
konwar
howev
sinc
breast
cancer
cell
normal
breast
tissu
directli
express
chavey
et
al
venetsanako
et
al
high
express
might
result
rather
reason
cancer
progress
also
whether
could
activ
expand
tumorresid
cell
yet
unclear
breast
cancer
suggest
could
function
replac
prolifer
cell
stimul
antibodi
oft
studi
found
work
synergist
enhanc
surviv
prolifer
activ
cell
result
elev
overal
cytotox
respons
regulatori
cell
treg
counteract
synergi
possibl
deplet
level
cultur
directli
suppress
synthesi
breast
tumor
cytotox
tumorinfiltr
cell
low
could
enhanc
exogen
use
human
sampl
studi
procedur
approv
ethic
committe
second
peopl
hospit
yunnan
provinc
written
inform
consent
particip
seven
breast
cancer
patient
mean
age
year
sd
year
grade
iii
stage
iia
iib
insitu
invas
ductal
carcinoma
recruit
studi
clinic
data
analyz
dicat
vancouv
canada
patient
seven
agematch
healthi
control
donat
peripher
blood
sampl
resect
tumor
sampl
peripher
blood
mononuclear
cell
pbmc
harvest
standard
ficol
thermo
fisher
gradient
centrifug
method
tumor
minc
small
piec
digest
tripl
enzymat
digest
mix
mgml
collagenas
mgml
hyaluronidas
uml
dnase
sigma
h
c
shake
water
bath
tumor
cell
suspens
filter
wash
tumor
mononuclear
cell
harvest
ficol
gradient
centrifug
unless
otherwis
specifi
cell
cultur
cellsml
rpmi
supplement
fb
glutamin
penicillinstreptomycin
thermo
fisher
cell
deplet
antihuman
antibodi
clone
magnet
bead
miltenyi
biotec
appli
peripher
blood
tumor
mononuclear
cell
follow
manufactur
instruct
separ
cell
cell
untouch
cell
first
isol
cell
isol
kit
human
miltenyi
biotec
microbead
ii
human
miltenyi
biotec
appli
follow
manufactur
instruct
level
sera
healthi
control
breast
cancer
patient
measur
use
human
elisa
kit
thermo
fisher
accord
manufactur
instruct
cytokin
stimul
ngml
recombin
human
r
system
andor
ngml
recombin
human
r
system
ad
cell
cultur
procedur
carri
dark
ice
experi
cell
wash
incub
first
violet
dead
cell
stain
thermo
fisher
min
wash
twice
differ
combin
surfac
antibodi
includ
antihuman
bd
bioscienc
min
experi
annexin
v
apoptosi
detect
kit
ebiosci
factor
stain
buffer
set
ebiosci
appli
follow
manufactur
instruct
assess
cell
prolifer
cfse
cell
prolifer
kit
thermo
fisher
appli
begin
incub
follow
manufactur
instruct
label
ci
na
cro
sigma
h
c
wash
plate
target
cell
per
well
plate
small
portion
pbmc
tumor
mononuclear
cell
stain
antihuman
antibodi
determin
percentag
cell
cultur
number
cell
ad
target
cell
calcul
cell
effector
target
ratio
indic
experi
spontan
releas
control
effector
cell
ad
maximum
releas
control
triton
ad
lyse
target
cell
h
incub
c
sampl
harvest
centrifug
l
supernat
transfer
polystyren
tube
gamma
count
percentag
specif
lysi
calcul
releas
experimentspontan
releas
maximum
releasespontan
releas
experi
perform
triplic
statist
analys
perform
prism
softwar
graphpad
twotail
p
valu
smaller
consid
statist
signific
synergist
increas
surviv
activ
quiescent
cell
cell
consid
main
effector
cell
antitumor
immun
respons
kilinc
et
al
demonstr
antiapoptot
function
cell
liu
et
al
oft
first
found
breast
cancer
patient
present
elev
serum
level
healthi
individu
fig
compar
contrast
role
cell
surviv
pbmc
breast
cancer
individu
unstimul
stimul
cell
receptor
tcr
monoclon
antibodi
presenc
addit
cytokin
none
addit
addit
addit
cell
deplet
could
secret
high
amount
produc
confound
result
surviv
fig
andor
addit
significantli
improv
surviv
tcrstimul
cell
serum
level
agematch
healthi
control
breast
cancer
bc
patient
measur
elisa
triplic
experi
statist
differ
healthi
bc
group
examin
ttest
welch
correct
b
nonapoptot
cell
gate
annexin
vneg
cell
cell
cell
shown
gate
live
cell
tcrstimul
sampl
c
percentag
viabl
cell
annexin
vneg
h
black
bar
h
gray
bar
unstimul
media
tcrstimul
gml
statist
differ
experiment
group
correspond
none
control
group
examin
use
twoway
anova
follow
dunnett
test
bar
repres
sem
ns
signific
p
p
cell
examin
fig
shortterm
h
incub
signific
differ
apoptosi
level
cell
among
variou
treatment
condit
observ
fig
howev
longerterm
h
incub
tcrstimul
cell
addit
either
suppress
level
apoptosi
compar
addit
cytokin
fig
ad
increas
surviv
rate
tcrstimul
cell
higher
increas
alon
alon
combin
interestingli
effect
observ
tcrstimul
unstimul
cell
viabil
tcrstimul
cell
present
lower
viabil
unstimul
cell
addit
cytokin
ad
fig
synergist
increas
level
cell
cytotox
like
due
improv
prolifer
activ
cell
next
examin
effect
cellmedi
cytotox
chromium
releas
assay
shortterm
h
tcrstimul
cell
signific
differ
cytotox
among
none
treatment
found
fig
howev
longterm
h
tcrstimul
cell
none
group
present
significantli
reduc
cytotox
compar
shortterm
tcrstimul
none
group
wherea
group
demonstr
compar
cytotox
correspond
shortterm
group
fig
longterm
group
demonstr
significantli
elev
cytotox
compar
shortterm
group
investig
increas
longterm
cytotox
cell
examin
prolifer
tcrstimul
cell
variou
cytokin
treatment
fig
alon
promot
prolifer
tcrstimul
cell
alon
significantli
increas
prolifer
tcrstimul
cell
combin
result
highest
frequenc
divid
cell
fig
inde
group
contain
highest
number
cell
h
tcrstimul
fig
previou
experi
deplet
cell
avoid
potenti
confound
effect
due
cytokin
product
cell
howev
treg
cell
shown
crucial
antiinflammatori
properti
breast
cancer
curiel
watanab
et
al
therefor
decid
examin
action
treg
cell
effect
cell
repres
canon
transcript
factor
treg
cell
cell
concentr
fraction
cell
fig
c
fraction
total
cell
fraction
greater
puriti
fraction
puriti
fraction
fig
fraction
ad
tcrstimul
fig
andor
addit
help
tcrstimul
cell
maintain
cytotox
breast
cancer
cell
line
label
use
target
cell
specif
lysi
correspond
spontan
releas
level
specif
lysi
correspond
releas
level
triton
use
lyse
target
cell
shortterm
h
tcrstimul
cell
none
condit
use
effector
cell
b
longterm
h
tcrstimul
cell
none
condit
use
effector
cell
statist
differ
experiment
group
correspond
none
control
group
examin
use
twoway
anova
follow
dunnett
test
bar
repres
sem
ns
signific
p
p
p
deplet
pbmc
cultur
addit
addit
cell
significantli
chang
cytotox
prolifer
tcrstimul
cell
addit
treg
significantli
suppress
cytotox
prolifer
tcrstimul
cell
fig
next
investig
effect
treg
cell
concentr
found
addit
treg
cell
significantli
reduc
concentr
cell
numberdepend
manner
fig
howev
treg
cell
directli
suppress
transcript
mrna
cell
fig
addit
treg
cell
significantli
chang
concentr
cultur
transcript
mrna
fig
synergisitc
increas
cytotox
tumorinfiltr
cell
could
suppress
treg
next
investig
effect
tumorinfiltr
cell
freshli
isol
tumorinfiltr
cell
present
limit
cytotox
fig
neither
alon
alon
suffici
rescu
cytotox
tumorinfiltr
cell
howev
ad
cytotox
tumorinfiltr
cell
significantli
increas
similar
pbmc
enhanc
tumorinfiltr
cell
cytotox
significantli
suppress
treg
cell
ad
fig
immun
system
involv
almost
everi
step
tumor
pathobiolog
chronic
inflamm
angiogen
tumor
promot
cytotox
immun
respons
crucial
tumor
fig
andor
addit
increas
prolifer
tcrstimul
cell
cell
pbmc
label
cfse
tcrstimul
monoclon
antibodi
gml
h
harvest
flow
cytometri
examin
percentag
divid
cell
bold
number
gate
cfselow
cell
panel
shown
alreadi
gate
cell
b
frequenc
divid
cell
none
condit
h
tcrstimul
cell
c
number
cell
count
flow
cytomet
end
h
tcrstimul
start
cell
per
condit
statist
differ
experiment
group
correspond
none
control
group
examin
oneway
anova
follow
dunnett
test
bar
repres
sem
ns
signific
p
p
treg
cell
suppress
enhanc
cell
function
deplet
concentr
treg
cell
cell
ad
tcrstimul
cell
cultur
h
viabil
b
cytotox
et
c
level
prolifer
cell
examin
statist
differ
experiment
condit
control
examin
oneway
anova
follow
dunnett
test
supernat
level
treg
ad
variou
concentr
h
tcrstimul
pbmc
condit
supplement
gml
gml
initi
e
mrna
express
cell
end
h
incub
rel
gapdh
mrna
level
e
statist
differ
experi
control
examin
twoway
anova
follow
dunnett
test
bar
repres
sem
ns
signific
p
p
p
surveil
elimin
grow
amount
evid
suggest
regulatori
cytokin
antitumor
immun
respons
proinflammatori
antiinflammatori
action
implic
develop
well
suppress
tumor
tumorsuppress
side
inhibit
inflamm
tumor
necrosi
factor
tnf
enrich
could
exert
tumorigen
effect
langowski
et
al
also
induc
activ
expans
tumorresid
cell
emmerich
et
al
tumorpromot
side
highli
express
cancer
breast
tissu
normal
breast
tissu
associ
higher
grade
breast
cancer
studi
chavey
et
al
hamidullah
changkija
konwar
contrast
observ
suggest
precis
role
cancer
fig
synergist
improv
cytotox
tumorinfiltr
cell
could
suppress
treg
cell
freshli
isol
tumorinfiltr
mononuclear
cell
tcr
stimul
none
condit
h
cytotox
tumorinfiltr
cell
examin
et
ratio
statist
differ
experi
none
control
examin
oneway
anova
follow
dunnett
test
b
variou
concentr
circul
treg
cell
ad
tcrstimul
tumorinfiltr
cell
h
incub
cytotox
examin
et
ratio
statist
differ
experi
control
examin
oneway
anova
follow
dunnett
test
bar
repres
sem
ns
signific
p
p
contextdepend
studi
show
full
antitumor
capac
like
requir
concurr
presenc
first
found
longterm
tcr
stimul
cell
breast
cancer
patient
tend
undergo
apoptosi
phenomenon
suppress
andor
fig
cytotox
tcrstimul
cell
also
tend
decreas
time
trend
could
revert
fig
significantli
increas
level
prolifer
tcrstimul
cell
fig
combin
result
seem
function
primarili
improv
surviv
prolifer
tcrstimul
cell
similar
role
previous
discov
acut
coronavirusinduc
enceph
highli
activ
cell
transient
express
maintain
cytotox
function
trandem
et
al
notabl
addit
demonstr
synergist
effect
present
improv
cell
surviv
prolifer
cytotox
higher
sum
improv
mediat
individu
cytokin
furthermor
tumorinfiltr
cell
present
low
cytotox
could
rescu
neither
alon
combin
effect
fig
togeth
studi
offer
possibl
explan
partial
disagre
observ
regard
role
cancer
specif
outcom
enrich
depend
studi
also
suggest
combin
might
incorpor
futur
immunotherapi
synergist
effect
suscept
addit
treg
sinc
treg
significantli
deplet
even
cytokin
ad
exogen
concentr
significantli
higher
physiolog
concentr
fig
treg
cell
known
increas
risk
metastasi
breast
cancer
precis
mechan
unknown
watanab
et
al
result
suggest
treg
cell
possibl
modifi
cytokin
milieu
elimin
synergi
result
reduc
prolifer
cytotox
cell
limit
present
studi
first
found
breast
cancer
patient
higher
serum
concentr
healthi
individu
suggest
immun
system
activ
breast
cancer
patient
fig
howev
concentr
intratumor
examin
cohort
patient
due
lack
tumor
sampl
also
unclear
tumorinfiltr
cell
present
lower
cytotox
correspond
peripher
blood
cell
normal
breast
tissu
resect
togeth
tumor
tissueinfiltr
cell
could
recov
therefor
normal
control
lack
experi
perform
tumorinfiltr
cell
furthermor
major
conclus
deriv
use
isol
pbmc
subset
vitro
environ
ignor
potenti
vivo
interact
therefor
studi
anim
model
necessari
confirm
concentr
function
interact
tumor
microenviron
none
